1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI).

Saved in:
Bibliographic Details
Title: 1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI).
Authors: Costa Svedman, F.1 (AUTHOR), Liapi, M.2 (AUTHOR), Chatzidionysiou, A.2 (AUTHOR), Månsson-Broberg, A.3 (AUTHOR), Egyhazi Brage, S.4 (AUTHOR)
Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS688-S689. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2023.09.2286